Cat. No. 0793
Alternative Name: RX 781094
Chemical Name: 2-(1,4-Benzodioxan-2-yl)-2-imidazol
Biological Activityα2-adrenoceptor antagonist, and I2 ligand, selective over I1 sites (pKi values are 5.90, 7.22, 8.01, 7.43, and 7.7 for I1, I2, α2A, α2B, and α2C receptors respectively).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Eglen et al (1998) 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. TiPS 19 381. PMID: 9786027.
Berdeu et al (1995) Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat. Eur.J.Pharmacol. 275 91. PMID: 7774667.
Michel and Ernsberger (1992) Keeping an eye on the I site: imidazoline-preferring receptors. TIPS 13 369. PMID: 1413085.
Dabir (1986) Idazoxan: a novel pharmacological tool for the study of α2-adrenoceptors. J.Pharmacol. 17 113. PMID: 2875218.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for Idazoxan hydrochloride include:
Sadeghi et al (2015) μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons. Development 172 460. PMID: 24372103.
Bucher et al (2014) Medullary norepinephrine neurons modulate local oxygen concentrations in the bed nucleus of the stria terminalis. J Cereb Blood Flow Metab 34 1128. PMID: 24714037.
Do you know of a great paper that uses Idazoxan hydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Idazoxan hydrochloride, supplier, α2-adrenoceptor, alpha2-adrenoceptor, a2-adrenoceptor, a2-adrenergic, α2-Adrenergic, alpha2-Adrenergic, antagonists, I2, ligand, Receptors, Imidazoline, RX781094, Tocris Bioscience, Adrenergic α2 Receptor Antagonist products
Find multiple products by catalog number
April 1 - 5, 2017
Washington, D.C., USA